New drug for multiple sclerosis! Novart Kesimpta: The first subsethic B-cell therapy available at home once a month, won the favor of patients/nurses!

February 17, 2021 // -- Novartis recently released a new multicenter survey that shows that the treatment of multiple sclerosis (FOR MS), patients and caregivers prefer to use Sensoready auto-injectors for self-dosing Kesimpta (ofatumumab) rather than auto-injectors for other disease-correcting therapies (84% vs. 16%).
survey found that Sensoready auto-injectors ranked highest in terms of "easy-to-use pen self-injection," "patients can use independently," and "easy preparation and setup for patients and nurses" compared to auto-injectors for other disease-correcting therapies on the market.
data will be presented at the 6th Annual Meeting of the Inter-American Multiple Sclerosis Treatment and Research Council (ACTRIMS) on February 25-27, 2021.
data continue to show that Kesimpta has the potential to be the preferred treatment option, as the ease of use of the drug plays an important role in patient satisfaction and treatment compliance. amy Perrin Ross,
multiple sclerosis nurse, said: "As an MS nurse, I have to know that people with multiple sclerosis with me will be able to successfully treat themselves.
easy to install and use with Sensoready auto-injection pens, MS patients can be treated independently and comfortably with confidence.
Estelle Vester Blokland, head of global neuroscience medicine at Novartis Pharmaceuticals, said: "For patients with chronic conditions such as multiple sclerosis (MS), access to effective treatment and life flexibility are critical.
At Novargo, we are committed to redesigning drugs and solutions that enable patients to use them alone in the comfort of their homes through safe and efficient treatments to maintain this flexibility in their daily lives.
"Kesimpta is a new drug developed by Novartis for multiple sclerosis (MS) that was approved by the FDA in August 2020 as a subcute injection for the treatment of adult patients with multiple sclerosis (RMS), including clinical isolation syndrome, relapsed remission-relieving disease, and active secondary progressive disease.
the drug is currently under EU review and is expected to be reviewed in the first half of 2021.
Kesimpta is a new targeted B-cell therapy that shows very high efficacy and similar safety compared to the first-line drug Aubagio for multiple sclerosis (MS) and will be the preferred treatment for a wide range of RMS patients.
Aobagio is Sanofi's oral multiple sclerosis (MS) drug and the industry's leading MS oral disease correction drug.
results from two key Phase III ASCLEPIOS studies show that Kesimpta reduced annual recurrence rate (AAR) by more than 50 percent and the relative risk of confirming disability progress (CDP) by more than 30 percent compared to Aubagio.
addition, Kesimpta significantly reduced Gd-T1 brain damage and new/expanded T2 lesions compared to Aubagio.
independent post-mortem analysis showed that Kesimpta may have prevented new disease activity in RMS patients, and nearly 90 percent of patients treated with Kesimpta showed no signs of disease activity (NEDA-3) in the second year of treatment.
it's worth noting that Kesimpta is the first and only B-cell therapy that can be easily drugied and managed at home, with Sensoready auto-injection pen administration once a month.
traditionally, B-cell binders/consumption agents that treat MS are given primarily in hospitals or infusion centers, which increases the cost of the health care system and places a lifestyle burden on some patients.
Kesimpta is a very effective B-cell therapy that is given once a month under subsulverts and can be treated at home by the patient himself or herself, avoiding hospital/infusion centres, which will meet the significant needs of the RMS patient population.
goal of managing RMS is to maintain neurological function to slow the deterioration of dysfunction.
most RMS patients experience disease activity, although several disease-correcting therapies (DMTs) are available to treat RMS.
evidence that early and efficient treatment can improve long-term prognostication in RMS patients.
ofatumumab is an all-human anti-CD20 monoantigen that works by binding CD20 molecules on the surface of B cells and inducing effective B cell dissolution and depletion.
was first approved by the FDA in 2009 and sold under the commercial name Arzerra for the treatment of chronic lymphocytic leukemia (CLL), a drug that requires high-dose intravenous infusions at medical facilities.
novart then studied the treatment of RMS in a new development project because it was well known that B cells played a key role in the development of autoimmune diseases such as MS.
in RMS, ofatumab's clinical development program has been under way for 10 years, involving more than 2,300 patients worldwide as part of a rigorous study that reflects a broad patient population.
Kesimpta works in a unique way, and treatment options (drug treatment) are specifically designed for RMS and play a key role in outcomes.
this is a different administration option and pathway, unlike previously approved CLL adaptations.
Novarous MS portfolio Kesimpta as a next-generation B-cell depletion agent with faster B-cell depletion and immunity-friendly safety features The drug, which also has the convenience of self-administration with monthly subsurfic injections, is expected to challenge Roche's fast-growing CD20 targeted drug Ocrelizumab, which is expected to see global sales rise 57 percent to a staggering SFr3,708 million in 2019.
multiple sclerosis (MS) affects about 2.3 million people worldwide by disrupting normal functioning of the brain, optic nerve and spinal cord through inflammation and tissue damage.
The disease is usually divided into three types: relapsed-remission multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS, commonly defined as cognitive and physical changes and overall accumulation of disability), and primary progressive multiple sclerosis (PPMS).
about 85% of patients initially develop a recurrence type of multiple sclerosis.
in this area, Novart's portfolio includes Gilenya (fingolimod, S1P regulator), Mayzent (siponimod, next-generation S1P regulator), and Extavia (interferon β-1b for subsutil injections).
addition, Sanders sells Gatopa (Gratide acetate, 20mg/mL, 40mg/mL) in the United States, a generic of the Teva heavy MS drug Copaxone.
() Original origin: Novartis data show multiple sclerosis patients and nurses prefer Kesimpta® (ofatumab) Sensoready® autoinjector pen<!--/ewebeditor:page->